ATX101

The name ATX101 refers to two distinct investigational products currently in clinical development. The first is a potential first-in-class, host-directed therapeutic for **septic shock** licensed by Aurobac Therapeutics from Boehringer Ingelheim. This ATX101 is administered intravenously and works by targeting the loss of vascular integrity to treat severe infections. The second is a non-opioid, sustained-release **bupivacaine implant** developed by Allay Therapeutics for the management of post-surgical pain. This formulation is designed to provide localized analgesia following procedures such as total knee arthroplasty (TKA) by delivering high concentrations of bupivacaine directly to the surgical site over an extended period. Note: ATX-101 was also the historical code name for deoxycholic acid (Kybella), though it is not the primary focus of current clinical trial activities under this identifier in the provided context.